于本公告日期，认购人为公司的控股股东，因此为公司于上市规则项下的关联人士。 药明合联(02268)公布，于2025年9月3日(联交所交易时段前)，该公司与认购人药明生物(02269)订立认购 协议，拟向认购人发行2413.4万股认购股份，认购价为每股认购股份58.85港元(与配售价相同)，总代价 约为14.2亿港元。 认购事项净筹约14.14亿港元，约90%将用于进一步扩大集团的服务能力及产能，包括但不限于其生物 偶联药物、原料药及药品的临床及商业生产产能。约10%将用于集团的营运资金需求及一般公司用途。 ...

General Provisions - The company aims to protect the legal rights of the company, shareholders, employees, and creditors, and to regulate its organization and behavior according to relevant laws and regulations [1][4] - The company is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2] - The registered capital of the company is 70 million RMB [3] Business Objectives and Scope - The company's business objective is to establish a new operating mechanism through joint investment by shareholders and to promote the Xgimi brand globally [4][5] - The business scope includes software development, technical services, manufacturing of household appliances, and various sales and advertising activities [5] Shares - The company's shares are in the form of stocks, including domestic shares (A-shares) and overseas listed shares (H-shares) [7] - The issuance of shares follows principles of openness, fairness, and justice, ensuring equal rights for each share of the same category [7][8] - The company has a total of 3,675,000 shares issued, with specific details on the shareholding structure provided [8] Shareholders and Shareholder Meetings - The company recognizes the rights of shareholders to receive dividends, participate in meetings, and supervise the company's operations [16][35] - Shareholders holding more than 10% of shares can request the board to convene a temporary shareholder meeting [30][31] - The company must provide adequate notice for shareholder meetings, including details on the agenda and voting procedures [62][64] Board of Directors and Management - The board of directors is responsible for the overall governance of the company, including the appointment of senior management [19][22] - The company has established an audit committee to oversee financial practices and ensure compliance with regulations [19] Financial Accounting and Auditing - The company is required to maintain a financial accounting system and conduct regular audits to ensure transparency and accountability [4][19] - Profit distribution and financial responsibilities are clearly defined within the company's articles of association [4][19] Amendments to Articles of Association - The articles of association can be amended following the procedures outlined in the document, requiring approval from the shareholders [10][26]

Core Viewpoint - China Jinshi (01380.HK) has entered into a conditional subscription agreement with Liu Desheng to issue 11.236 million shares at a subscription price of HKD 0.178 per share, totaling HKD 2 million [1] Group 1 - The subscription shares represent approximately 3.03% of the existing issued shares as of the announcement date and approximately 2.94% of the enlarged issued shares post-completion [1] - The proceeds from the subscription are intended for general working capital, business development, and expansion, including funding for the acquisition of mining rights in Chile [1]

Core Viewpoint - China Jinshi (01380) announced a conditional subscription agreement with six subscribers to issue a total of 95.56 million subscription shares at a price of HKD 0.178 per share, raising approximately HKD 17 million [1] Group 1 - The total number of subscription shares represents approximately 25.8% of the existing issued shares as of the announcement date and about 20.5% of the enlarged issued shares post-completion, assuming no other changes in issued shares [1] - The estimated total proceeds from the subscription are approximately HKD 17 million, with a net amount of about HKD 16.7 million after deducting related expenses, equating to a net subscription price of approximately HKD 0.175 per share [1] - The proceeds from the subscription are intended for general working capital purposes and for the development and expansion of the group's business, including funding for the acquisition of mining rights in Chile [1]

经扣除专业费用及其他相关开支后，认购事项的所得款项净额约为7470万港元(按每股认购股份0.03港 元计)，本公司拟将所得款项净额用于偿还本集团流动负债项下的银行贷款及其他借贷;及本集团的一般 营运资金。 智通财经APP讯，北方矿业(00433)发布公告，认购协议所载的所有先决条件已经达成，而认购事项已于 2025年8月18日完成。认购人亦已根据认购协议的条款及条件按每股认购股份0.03港元的认购价合共认 购24.905亿股认购股份。 ...

Group 1 - The company China Antibody-B (03681) announced the issuance of 157 million subscription shares to the subscribers based on the subscription agreement on August 15, 2025 [1]

Group 1 - TCL Technology Group Co., Ltd. was established on July 17, 1997, and became a joint-stock company in 2002, listed on the Shenzhen Stock Exchange in 2004 [2] - The company plans to acquire 21.5311% equity of Shenzhen Huaxing Optoelectronics Technology Co., Ltd. through issuing shares and cash payment, as approved by the China Securities Regulatory Commission [2] - The company will issue 1,035,489,574 shares at a price of RMB 4.21 per share, increasing its registered capital to RMB 20,800,862,447 [2] Group 2 - As of August 8, 2025, the company has raised a total of RMB 4,300,995,724.98 after deducting issuance costs [2] - The total issuance costs amounted to RMB 61,920,304.45, with a net amount raised after costs being RMB 4,300,995,724.98 [2] - The main underwriter for the issuance is Shenwan Hongyuan Securities Co., Ltd., and the bank has confirmed the funds transferred to the company's account [2]

Group 1 - The company, Fourth Paradigm (06682), announced that all conditions of the placement agreement have been met, and the completion of the subscription agreement is set for August 14, 2025 [1] - A total of 25.9 million subscription shares have been issued at a subscription price of HKD 50.50 per share, representing approximately 8.78% of the issued H shares before completion and about 5.25% of the total issued shares [1] - The issuance of subscription shares will increase the total number of issued H shares by approximately 8.07% and the total issued shares by about 4.98% [1]

Group 1 - North Sea Kangcheng-B signed a subscription agreement with Baiyang Health Industry International Trade Co., Ltd. to issue 74.9715 million shares at HKD 1.34 per share, representing a discount of approximately 19.76% compared to the previous trading day's closing price [2] - The subscription is expected to raise HKD 100 million, with net proceeds estimated at approximately HKD 98.6618 million, which will be used for product research and development, marketing promotion, loan repayment, and daily operations [2] - The company's shares will be suspended from trading starting at 9:00 AM on August 12, 2025, and will resume trading at 9:00 AM on August 13, 2025 [2]

Core Viewpoint - The company, 北海康成-B (01228), has entered into a subscription agreement with 百洋健康产业国际商贸有限公司 to issue 74.9715 million shares at a subscription price of HKD 1.34 per share, representing a discount of approximately 19.76% from the closing price of HKD 1.67 on August 11, 2025 [1] Group 1 - The total amount raised from the subscription will be HKD 100 million, with a net amount estimated at approximately HKD 98.6618 million after deducting related expenses [1] - The net proceeds from the subscription are intended to be used for (i) research and development of commercialized products; (ii) marketing and promotional activities; (iii) repayment of loan financing and borrowings; and (iv) general operational activities of the group [1] - Trading of the company's shares was suspended on the Hong Kong Stock Exchange from 9:00 AM on August 12, 2025, at the request of the company, pending the announcement [1]